Minimal removal of raltegravir by hemodialysis in HIV-infected patients with end-stage renal disease

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 7, 2010, Pages 3047-3048

  Moltó, José ^a   Sanz Moreno, José ^b   Valle, Marta ^c   Cedeño, Samandhy ^a   Bonal, Jordi ^a   Bouarich, Hanane ^b   Clotet, Bonaventura ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; NEVIRAPINE; RALTEGRAVIR; RITONAVIR PLUS TIPRANAVIR; VIRUS RNA; 2 PYRROLIDONE DERIVATIVE; INTEGRASE INHIBITOR;

ADULT; ARTICLE; BLOOD SAMPLING; CASE REPORT; CLEARANCE; DRUG BLOOD LEVEL; HEMODIALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; VIRUS LOAD; BLOOD; HIV INFECTIONS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PROCEDURES; RENAL REPLACEMENT THERAPY;

HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PYRROLIDINONES; RENAL DIALYSIS;

EID: 77953770958     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00363-10     Document Type: Article

References (9)

1. Emem, C. P., F. Arogundade, A. Sanusi, K. Adelusola, F. Wokoma, and A. Akinsola. 2008. Renal disease in HIV-seropositive patients in Nigeria: an assessment of prevalence, clinical features and risk factors. Nephrol. Dial. Transplant. 23:741-746.
2. Gibaldi, M., and D. Perrier. 1975. Drugs and the pharmaceutical sciences, vol. 1. Pharmacokinetics. Marcel Dekker, New York, NY.
3. Giguére, P., C. la Porte, G. Zhang, and B. Cameron. 2009. Pharmacokinetics of darunavir, etravirine and raltegravir in an HIV-infected patient on haemodialysis. AIDS 23:740-742.
4. Laufer, R., O. G. Paz, A. Di Marco, F. Bonelli, E. Monteagudo, V. Summa, and M. Rowley. 2009. Quantitative prediction of human clearance guiding the development of raltegravir (MK-0518, Isentress) and related HIV integrase inhibitors. Drug Metab. Dispos. 37:873-883.
5. Lennox, J. L., E. DeJesus, A. Lazzarin, R. B. Pollard, J. V. Madruga, D. S. Berger, J. Zhao, X. Xu, A. Williams-Diaz, A. J. Rodgers, R. J. Barnard, M. D. Miller, M. J. DiNubile, B. Y. Nguyen, R. Leavitt, P. Sklar, and STARTMRK Investigators. 2009. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374:796-806.
6. Mocroft, A., O. Kirk, J. Gatell, P. Reiss, P. Gargalianos, K. Zilmer, M. Beniowski, J. P. Viard, S. Staszewski, and J. D. Lundgren. 2007. Chronic renal failure among HIV-1-infected patients. AIDS 21:1119-1127.
7. Poirier, J. M., P. Robidou, and P. Jaillon. 2008. Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 867:277-281.
8. Schwartz, E. J., L. A. Szczech, M. J. Ross, M. E. Klotman, J. A. Winston, and P. E. Klotman. 2005. Highly active antiretroviral therapy and the epidemic of HIV + end-stage renal disease. J. Am. Soc. Nephrol. 16:2412-2420.
9. Steigbigel, R. T., D. A. Cooper, P. N. Kumar, J. E. Eron, M. Schechter, M. Markowitz, M. R. Loutfy, J. L. Lennox, J. M. Gatell, J. K. Rockstroh, C. Katlama, P. Yeni, A. Lazzarin, B. Clotet, J. Zhao, J. Chen, D. M. Ryan, R. R. Rhodes, J. A. Killar, L. R. Gilde, K. M. Strohmaier, A. R. Meibohm, M. D. Miller, D. J. Hazuda, M. L. Nessly, M. J. DiNubile, R. D. Isaacs, B. Y. Nguyen, H. Teppler, and BENCHMRK Study Teams. 2008. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359:339-354.